Compare Ambarella Inc (AMBA) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ambarella Inc vs Humana Inc — how do they compare? Ambarella Inc trades at $83.24 (market cap $3.60B), while Humana Inc trades at $374.25 (market cap $46.31B). The key difference: Humana Inc is far larger — about 12.9× Ambarella Inc's market cap, and Humana Inc pays a 0.92% dividend while Ambarella Inc pays none. Which is the better fit depends on your goals.
| AMBA | HUM | |
|---|---|---|
Market Cap | $3.60B | $46.31B |
Sector | Technology | Health |
52-Week High | $95.51 | $409.42 |
52-Week Low | $48.65 | $163.67 |
Enterprise Value | $3.33B | $53.67B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $86.78, up 3.57% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics. Recent news highlights NXP's potential acquisition interest and the company's strategic pivot to edge AI chips, driving analyst optimism. Q2 2026 earnings are expected at $0.171 per share, following three consecutive quarterly beats. Revenue growth is projected to accelerate from $285M in 2025 to $405M in 2026.
Outlook remains positive with 58% analyst buy ratings and $108.67 price target, but risks include persistent net losses, high valuation multiples, and competitive pressure in semiconductor space. The edge AI transition offers growth potential, yet execution risks and insider selling warrant caution for investors.
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ambarella Inc
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
